{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:53:15Z","timestamp":1740106395290,"version":"3.37.3"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004242","name":"Princess Nourah Bint Abdulrahman University","doi-asserted-by":"publisher","award":["PNURSP2023R167"],"award-info":[{"award-number":["PNURSP2023R167"]}],"id":[{"id":"10.13039\/501100004242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cyto.2023.156433","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:12:01Z","timestamp":1700075521000},"page":"156433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients"],"prefix":"10.1016","volume":"173","author":[{"given":"Mohamed","family":"Abdel-Salam Elgohary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumaiah","family":"J.Alarfaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Ibrahim Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Medhat Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Emam Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mahmoud Elkholy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaa A.","family":"El-Masry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacklin","family":"Samir kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Ali AbdelRahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashgan","family":"Wageh Saber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed G","family":"Seadawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed H.M.","family":"Elshishtawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-0719","authenticated-orcid":false,"given":"Maisra M.","family":"El-Bouseary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.cyto.2023.156433_b0005","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health CareWorkers, and health systems during the COVID-19Pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J. Am. Coll Cardiol."},{"key":"10.1016\/j.cyto.2023.156433_b0010","unstructured":"WHO. Coronavirus (COVID-19) Dashboard, Available from: https:\/\/covid19.who.int\/, Jan.27, 2023."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41182-021-00347-7","article-title":"V-2 antibody among individuals aged above 15years and residing in congregate settings in Dire Dawa cityadministration, Ethiopia","volume":"49","author":"Shaweno","year":"2021","journal-title":"Trop Med Health."},{"key":"10.1016\/j.cyto.2023.156433_b0020","doi-asserted-by":"crossref","unstructured":"F. Esfahanian, S. SeyedAlinaghi, N. Janfaza, M.M. Tantuoyir, Predictors of hospital mortality among patients with COVID-19 in Tehran, Iran. SAGE Open Med. 2021;9:20503121211051573. doi: 10.1177\/20503121211051573 PMID: 34676075.","DOI":"10.1177\/20503121211051573"},{"key":"10.1016\/j.cyto.2023.156433_b0025","doi-asserted-by":"crossref","unstructured":"H.L.M. Kox, Relative infectuousness of asymptomatic andsymptomatic COVID-19 infections\u2014analytical time table, MPRA Munich Personal RePEc Archive, 2021. Accessed 30 Jun 2021. https:\/\/mpra.ub.uni-muenchen.de\/108781\/1\/MPRA_paper_108781.Pdf.","DOI":"10.2139\/ssrn.3889535"},{"issue":"2","key":"10.1016\/j.cyto.2023.156433_b0030","doi-asserted-by":"crossref","first-page":"e0245772","DOI":"10.1371\/journal.pone.0245772","article-title":"In-hospital mortality from severe COVID-19 in a tertiary carecenter in Mexico City; causes of death, risk factors and theimpact of hospital saturation","volume":"16","author":"Olivas-Mart\u0131nez","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cyto.2023.156433_b0035","doi-asserted-by":"crossref","first-page":"e0249038","DOI":"10.1371\/journal.pone.0249038","article-title":"ICU outcomes and survival in patients with severe COVID-19 in the largesthealth care system in central Florida","volume":"16","author":"Oliveira","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2023.156433_b0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1186\/s12879-021-06369-0","article-title":"Predictors of mortality in patients with coronavirus disease 2019: a systematic review and metaanalysis","volume":"21","author":"Shi","year":"2021","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of Covid-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"20","key":"10.1016\/j.cyto.2023.156433_b0050","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/M20-6976","article-title":"The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review","volume":"174","author":"Oran","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"10229","key":"10.1016\/j.cyto.2023.156433_b0060","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.cyto.2023.156433_b0065","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndromelike disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2023.156433_b0075","article-title":"Cell pyroptosis, a potential pathogenic mechanism of 2019- nCoV infection","author":"Yang","year":"2020","journal-title":"SSRN Journal."},{"key":"10.1016\/j.cyto.2023.156433_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imlet.2020.06.013","article-title":"Lymphopenia during the COVID-19 infection: what it shows and what can be learned","volume":"225","author":"Tavakolpour","year":"2020","journal-title":"Immunol. Lett."},{"issue":"10223","key":"10.1016\/j.cyto.2023.156433_b0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0090","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ajcp\/aqaa062","article-title":"Covid-19 autopsies, Oklahoma, USA","volume":"153","author":"Barton","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cyto.2023.156433_b0095","article-title":"Macrophages: a Trojan horse in COVID-19?","volume":"20(6):351-","author":"Park","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2023.156433_b0100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","article-title":"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review","volume":"9","author":"Adhikari","year":"2020","journal-title":"Infect Dis Pover."},{"issue":"7798","key":"10.1016\/j.cyto.2023.156433_b0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"7888","key":"10.1016\/j.cyto.2023.156433_b0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/d41586-021-03614-z","article-title":"How bad is omicron? what scientists know so far","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.cyto.2023.156433_b0120","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.15585\/mmwr.mm7028e2","article-title":"SARSCoV-2 B.1.617.2 (delta) variant COVID-19 outbreak associated with aGymnastics facility Oklahoma, April-May 2021","volume":"70","author":"Dougherty","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"11","key":"10.1016\/j.cyto.2023.156433_b0125","volume":"10","author":"Molinaro","year":"2020","journal-title":"Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: an Additional Weapon against COVID-19? Nanomaterials (basel)."},{"key":"10.1016\/j.cyto.2023.156433_b0130","doi-asserted-by":"crossref","unstructured":"R.Q. Cron, R. Caricchio, W.W. Chatham, Calming the cytokine storm in COVID-19. NAture MediciNe | VOL 27 | OCTOBER 2021 | 1672\u20131678 | www. Nat Commun\/naturemedicine. 2021.","DOI":"10.1038\/s41591-021-01500-9"},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.cyto.2023.156433_b0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cytogfr.2020.05.002","article-title":"COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons","volume":"53","author":"Nile","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2023.156433_b0145","doi-asserted-by":"crossref","unstructured":"R.Q. Cron, No perfect therapy for the imperfect COVID-19 cytokine storm, www.the.Vol. 2022;4(5):e308-10. doi: 10.1016\/S2665-9913(22)00068-6 PMID: 35368388.","DOI":"10.1016\/S2665-9913(22)00068-6"},{"issue":"02","key":"10.1016\/j.cyto.2023.156433_b0150","first-page":"121","article-title":"Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment","volume":"39","author":"Commission","year":"2020","journal-title":"J. Tianjin Univ. Tradit. Chin. Med."},{"key":"10.1016\/j.cyto.2023.156433_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jir.2005.25.241","article-title":"IL-6 transsignaling: the in vivo consequences","volume":"25","author":"Jones","year":"2005","journal-title":"J. Interferon Cytokine Res."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab \u2013 a novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156433_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"10.1016\/j.cyto.2023.156433_b0175","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.chest.2020.06.006","article-title":"Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes","volume":"158","author":"Price","year":"2020","journal-title":"Chest"},{"issue":"49","key":"10.1016\/j.cyto.2023.156433_b0180","doi-asserted-by":"crossref","first-page":"30896","DOI":"10.1073\/pnas.2009961117","article-title":"Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?","volume":"117","author":"Wang","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.cyto.2023.156433_b0185","first-page":"20115758","article-title":"An inflammatory cytokine signature helps predict COVID-19 severity and death","volume":"28","author":"Del Valle","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0190","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/HYPERTENSIONAHA.118.10266","article-title":"Understanding angiotensin II Type 1 receptor signaling in vascular pathophysiology","volume":"71","author":"Eguchi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cyto.2023.156433_b0195","unstructured":"Empacta; 2020. Roche\u2019s Phase III EMPACTA study showed Actemra\/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. Available at: https:\/\/www. http:\/\/roche.com\/investors\/updates\/inv-update-2020-09-18.htm. Accessed 23Oct, 2020."},{"key":"10.1016\/j.cyto.2023.156433_b0200","unstructured":"Eparine a basso peso molecolare; 2020. Agenzia Italiana del Farmaco Eparine a basso peso molecolare nei pazienti adulti con COVID-19. Available at: https:. http:\/\/www.aifa.gov.it\/documents\/20142\/1123276\/Eparine_Basso_Peso_Molecolare_11.04.2020.pdf\/e30686fb-3f5e-32c9-7c5c-951cc40872f7."},{"key":"10.1016\/j.cyto.2023.156433_b0205","unstructured":"FDA news release; 2021. Tocilizumab emergency use authorization (EUA). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/newsevents\/press-announcements\/coronavirus-covid-19-update-fda-authorizesdrug-treatment-covid-19."},{"issue":"12","key":"10.1016\/j.cyto.2023.156433_b0210","doi-asserted-by":"crossref","first-page":"e0242763","DOI":"10.1371\/journal.pone.0242763","article-title":"A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2023.156433_b0215","doi-asserted-by":"crossref","unstructured":"L. Ghosn, A. Chaimani, T. Evrenoglou, M. Davidson, C. Gra\u00f1a, C. Schmucker, et al., Interleukin-6 blocking agents for treating COVID-19: a living systematic review, Cochrane Database Syst Revpmcid. 2021;3(3):CD013881PMC8406988. doi: 10.1002\/14651858.CD013881 PMID: 33734435.","DOI":"10.1002\/14651858.CD013881"},{"issue":"16","key":"10.1016\/j.cyto.2023.156433_b0220","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2023.156433_b0225","doi-asserted-by":"crossref","unstructured":"Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-84 30173-9 doi: 10.1016\/S2665-9913(20).","DOI":"10.1016\/S2665-9913(20)30285-X"},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0230","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.cyto.2023.156433_b0240","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","author":"Yong-gang","year":"2020","journal-title":"Biol. Res."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0245","first-page":"32","article-title":"CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA","volume":"181","author":"Hermine","year":"2021","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","article-title":"COVID-19: A new virus, but a familiar receptor and cytokine release syndrome","volume":"52","author":"Hirano","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.cyto.2023.156433_b0260","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2023.156433_b0265","doi-asserted-by":"crossref","unstructured":"J. Zhang, C. Chen, Y. Yang, J. Yang, Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19, A systematic review and meta-analysis. Medicine 101 (2022) 9.","DOI":"10.1097\/MD.0000000000028967"},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0270","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12879-021-05945-8","article-title":"Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients froma long-term care facility during Covid-19 outbreak","volume":"21","author":"Sabaka","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156433_b0275","unstructured":"Minstry of health and population (MOHP); coronavirus disease COVID 19. SARS COV. p. 2. Management guide. Version 1; 27 March 2020."},{"key":"10.1016\/j.cyto.2023.156433_b0280","unstructured":"Minstry of health and population (MOHP), Egypt; coronavirus disease COVID 19. SARS COV. p. 2. Management guide. Version 1.4; November 2020."},{"key":"10.1016\/j.cyto.2023.156433_b0285","doi-asserted-by":"crossref","unstructured":"M.A. Elgohary, E.M. Hasan, A.A. Ibrahim, M.F.A. Abdelsalam, R.Z. Abdel-Rahman, A.I. Zaki et al., Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial, J. Med. Life. 15(3, MARCH) (2022) 350-8. doi: 10.25122\/jml-2021-0175 PMID: 35449996.","DOI":"10.1101\/2021.05.19.21257429"},{"key":"10.1016\/j.cyto.2023.156433_b0290","unstructured":"World Health Organization (WHO), Clinical management of COVID 19, Interim guidance, 18 May 2020."},{"key":"10.1016\/j.cyto.2023.156433_b0295","doi-asserted-by":"crossref","unstructured":"G.A. Saeed, W. Gaba, A. Shah, A.A. Al Helali, E. Raidullah, A.B. Al Ali et al., Correlation between chest CT severity scores and the clinical parameters of adult patients with COVID-19 pneumonia, Rad Res Pract. 2021 6 January;2021:6697677. doi: 10.1155\/2021\/6697677 PMID: 33505722.","DOI":"10.1155\/2021\/6697677"},{"key":"10.1016\/j.cyto.2023.156433_b0300","unstructured":"Minstry of health and population (MOHP); coronavirus disease COVID 19. SARS COV. p. 2. Management guide. Version 1.8; July 2022."},{"key":"10.1016\/j.cyto.2023.156433_b0305","doi-asserted-by":"crossref","unstructured":"S. Zhang, L. Li, A. Shen, Y. Chen, Z. Qi, Rational use of tocilizumab in the treatment of novel coronavirus pneumo-nia, Clin. Drug Investig. 40(6) (2020) 511-8, doi: 10.1007\/s40261-020-00917-3.49, PMID: 32337664.","DOI":"10.1007\/s40261-020-00917-3"},{"key":"10.1016\/j.cyto.2023.156433_b0310","doi-asserted-by":"crossref","unstructured":"Y. Tang, J. Liu, D. Zhang, Cytokine Storm in COVID-19: the Current Evidence and Treatment Strategies. Frontiers in Immunology | www. frontiersin.org, 2020. Accessed 2 Jul 2020 | Volume 11 |:Article 1708.","DOI":"10.3389\/fimmu.2020.01708"},{"key":"10.1016\/j.cyto.2023.156433_b0315","doi-asserted-by":"crossref","unstructured":"M. Sheppard, F. Laskou, P.P. Stapleton, S. Hadavi, B. Dasgupta, Tocilizumab (actemra), Hum. Vaccin. Immunother. 13(9) (2017) 1972\u201388, doi: 10.1080\/21645515, PMID: 28841363.","DOI":"10.1080\/21645515.2017.1316909"},{"issue":"10","key":"10.1016\/j.cyto.2023.156433_b0320","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2023.156433_b0325","doi-asserted-by":"crossref","unstructured":"Recovery Collaborative Group. Tocilizumab inpatients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 1 May;397(10285):1637-45. doi: 10.1016\/S0140-6736(21)00676-0 PMID: 33933206.","DOI":"10.1016\/S0140-6736(21)00676-0"},{"issue":"16","key":"10.1016\/j.cyto.2023.156433_b0330","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0335","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2023.156433_b0340","doi-asserted-by":"crossref","unstructured":"E. Abidi, W.S. El Nekidy, E. Alefishat et al., Tocilizumab and COVID-19: Timing ofAdministration and Efficacy. Frontiers in Pharmacology | www. frontiersin.org. Accessed February 2022 | Volume 13 |:Article 825749.","DOI":"10.3389\/fphar.2022.825749"},{"issue":"4","key":"10.1016\/j.cyto.2023.156433_b0345","article-title":"Tocilizumab for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"92","author":"Boppana","year":"2022","journal-title":"Monaldi Arch. Chest Dis."},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0350","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/v13061067","article-title":"Efficacy of tocilizumab therapy in different subtypes of COVID-19 cytokine storm syndrome","volume":"13","author":"Oliynyk","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cyto.2023.156433_b0355","doi-asserted-by":"crossref","unstructured":"E.K. Stokes, L.D. Zambrano, K.N. Anderson, E.P. Marder, K.M. Raz, S. El Burai Felix, et al.m Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-65. (PMC Free article). doi: 10.15585\/mmwr.mm6924e2 PMID: 32555134.","DOI":"10.15585\/mmwr.mm6924e2"},{"key":"10.1016\/j.cyto.2023.156433_b0360","doi-asserted-by":"crossref","unstructured":"Patil SV, Gondhali G, Acharya A. Role of initial and follow-up IL-6 (interleukin-6) titre in COVID-19 pneumonia: A single center experience. Electron J Gen Med. 2022;19(5), em390 . e-ISSN: 2516-3507. doi: 10.29333\/ejgm\/12191.","DOI":"10.29333\/ejgm\/12191"},{"key":"10.1016\/j.cyto.2023.156433_b0365","unstructured":"B.E. Henderson, Shorter time from COVID-19 symptom onset to hospitalization linked to disease severity, death; 2020. https:\/\/www.news-medical.net\/news\/20200926\/Shorter-time-from-COVID-19-symptom-onset-to-hospitalization-linked-to-disease-severity-death.aspx."},{"issue":"7821","key":"10.1016\/j.cyto.2023.156433_b0370","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0375","article-title":"Fac- tors associated with deaths due to COVID-19 versus other causes: population- based cohort analysis of UK primary care data and linked national death reg- istrations within the OpenSAFELY platform","volume":"lanepe.2021.100109","author":"Bhaskaran","year":"2021","journal-title":"Lancet Reg Health Eur."},{"issue":"10296","key":"10.1016\/j.cyto.2023.156433_b0380","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(21)00799-6","article-title":"IS- ARIC4C investigators. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study","volume":"398","author":"Drake","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2023.156433_b0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","article-title":"Gender differences in patients with COVID-19: focus on severity and mortality","volume":"8","author":"Jin","year":"2020","journal-title":"Front. Public Health"},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0390","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jmv.25757","article-title":"COVID-19 patients\u2019 clinical characteristics, discharge rate, and fatality rate of meta-analysis","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cyto.2023.156433_b0395","doi-asserted-by":"crossref","unstructured":"The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances:the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)\u2014China. China CDC Wkly > 2020. 2020;2(8):113-22.","DOI":"10.46234\/ccdcw2020.032"},{"issue":"9","key":"10.1016\/j.cyto.2023.156433_b0400","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2105\/AJPH.90.9.1463","article-title":"Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States","volume":"90","author":"Walsh","year":"2000","journal-title":"Am. J. Public Health"},{"issue":"11","key":"10.1016\/j.cyto.2023.156433_b0405","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2105\/AJPH.2009.180273","article-title":"Burden of mortality associated with autoimmune diseases among females in the United Kingdom","volume":"100","author":"Thomas","year":"2010","journal-title":"Am. J. Public Health"},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0410","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.dsx.2020.07.053","article-title":"A proposed ABCD scoring system for patient\u2019s self assessment and at emergency department with symptoms of COVID-19","volume":"14","author":"Salunke","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.cyto.2023.156433_b0415","doi-asserted-by":"crossref","unstructured":"W. Liang, H. Liang, L. Ou, B. Chen, A. Chen, C. Li, et al., Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19, JAMA Int. Med. 180(8) (2020) 1081-9,. doi: 10.1001\/jamainternmed.2020.2033 PMID: 32396163.","DOI":"10.1001\/jamainternmed.2020.2033"},{"key":"10.1016\/j.cyto.2023.156433_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117163","article-title":"Anosmia is associated with lower in-hospital mortality in COVID-19","volume":"419","author":"Talavera","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.cyto.2023.156433_b0425","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/1945892420930954","article-title":"Prevalence and recovery from olfactory and gustatory dysfunctions in Covid-19 infection: a prospective multicenter study","volume":"34","author":"Chary","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"issue":"4","key":"10.1016\/j.cyto.2023.156433_b0430","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.anai.2020.07.023","article-title":"Smell loss is a prognostic factor for lower severity of coronavirus disease 2019","volume":"125","author":"Foster","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.cyto.2023.156433_b0435","article-title":"Prevalence of anosmia and ageusia in patients with COVID-19 at a primary health center, Doha, Qatar. Indian","volume":"1\u20137","author":"Al-Ani","year":"2020","journal-title":"J. Otolaryngol. Head Neck Surg."},{"issue":"10","key":"10.1016\/j.cyto.2023.156433_b0440","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1002\/jmv.27918","article-title":"Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: the ANOSVID study","volume":"94","author":"Mercier","year":"2022","journal-title":"J. Med. Virol."},{"issue":"11","key":"10.1016\/j.cyto.2023.156433_b0445","doi-asserted-by":"crossref","first-page":"e0240784","DOI":"10.1371\/journal.pone.0240784","article-title":"Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection","volume":"15","author":"Townsend","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2023.156433_b0450","article-title":"Shanbehzadeh M Association of chest CT severity score with mortality of COVID-19 patients: a systematic review and meta-analysis","volume":"1\u201314","author":"Zakariaee","year":"2022","journal-title":"Clin Transl Imaging."},{"key":"10.1016\/j.cyto.2023.156433_b0455","article-title":"Chest CT characteristics are strongly predictive of mortality in patients with COVID-19 pneumonia: a multicentric cohort study","volume":"29(6, June):851\u201360","author":"Mal\u00e9cot","year":"2022","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.cyto.2023.156433_b0460","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijid.2020.04.061","article-title":"Mild versus severe COVID-19: laboratory markers","volume":"95","author":"Velavan","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.cyto.2023.156433_b0465","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7883\/yoken.JJID.2020.463","article-title":"Association of interleukin-6 level with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19)","volume":"74","author":"Zhou","year":"2021","journal-title":"Jpn. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.cyto.2023.156433_b0470","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.31301","article-title":"Longitudinal association between markers of liver injury and mortality in COVID-19 in China","volume":"72","author":"Lei","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cyto.2023.156433_b0475","article-title":"Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19","author":"Moreno Diaz","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.cyto.2023.156433_b0480","doi-asserted-by":"crossref","unstructured":"M. Aziz, R. Fatima, R. Assaly, Elevated interleukin-6 and severe COVID-19: A meta-analysis, J. Med. Virol. 92(11) (2020) 2283-5. doi: 10.1002\/jmv.25948 [Published online ahead of print, 28Apr 2020]. PMID: 32343429.","DOI":"10.1002\/jmv.25948"},{"key":"#cr-split#-10.1016\/j.cyto.2023.156433_b0485.1","doi-asserted-by":"crossref","unstructured":"T. Liu, J. Zhang, Y. Yang, H. Ma, Z. Li, J. Zhang, et al., The role of interleukin-6 in monitoring the severe case of coronavirus disease 2019, EMBO Mol Med. 12","DOI":"10.15252\/emmm.202012421"},{"key":"#cr-split#-10.1016\/j.cyto.2023.156433_b0485.2","unstructured":"(7) (2020) e12421, doi: 10.15252\/emmm.202012421 [Published online ahead of print, 19May 2020]. PMID: 32428990."},{"issue":"1","key":"10.1016\/j.cyto.2023.156433_b0490","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect."},{"issue":"9","key":"10.1016\/j.cyto.2023.156433_b0495","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ni0901-777","article-title":"Sex differences in autoimmune disease","volume":"2","author":"Whitacre","year":"2001","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156433_b0500","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-128-2-199801150-00009","article-title":"Thepathophysiologic roles of interleukin-6 in human disease","volume":"128","author":"Papanicolaou","year":"1998","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.cyto.2023.156433_b0505","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/ajh.2011.113","article-title":"Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans","volume":"24","author":"Chamarthi","year":"2011","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.cyto.2023.156433_b0510","first-page":"17 pages","article-title":"Arterial hypertension and interleukins: potential therapeutic target or future diagnostic marker?","volume":"Article ID 3159283","author":"Tanase","year":"2019","journal-title":"Int J. Hypertens."},{"key":"10.1016\/j.cyto.2023.156433_b0515","doi-asserted-by":"crossref","unstructured":"R.H. Du, L.R. Liang, C.Q. Yang, W, Wang, T.Z. Cao, Li Met al.m Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study.EurRespirJ.2020;55(5):2000524[doi: 10.1183\/13993003.00524-2020][Pubmed:32269088].","DOI":"10.1183\/13993003.00524-2020"},{"key":"10.1016\/j.cyto.2023.156433_b0520","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3389\/fphar.2020.01093","article-title":"Dynamic interleukin-6 level changes as a prognostic indicator in patients with COVID-19","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.cyto.2023.156433_b0525","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0530","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.cyto.2023.156433_b0535","first-page":"327","article-title":"Induction of pro- inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.cyto.2023.156433_b0540","doi-asserted-by":"crossref","unstructured":"Y. Wang, Y. Chen, X. Zhou, Tocilizumab, an exploratory treatment for severe COVID-19 patients, Can. J. Infect. Dis. Med. Microbiol. 2022;2022:6375870:Article ID 6375870. doi: 10.1155\/2022\/6375870 PMID: 35308307.","DOI":"10.1155\/2022\/6375870"},{"issue":"4","key":"10.1016\/j.cyto.2023.156433_b0545","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2022.0189","article-title":"Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and ComorbiditiesThe I-TECH randomized clinical trial","volume":"182","author":"Lim","year":"2022","journal-title":"JAMA Intern. Med."},{"issue":"7","key":"10.1016\/j.cyto.2023.156433_b0550","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMe2209017","article-title":"Time to stop using ineffective Covid-19 drugs","volume":"387","author":"Abdool Karim","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cyto.2023.156433_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"15","key":"10.1016\/j.cyto.2023.156433_b0560","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.cyto.2023.156433_b0565","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156433_b0570","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"issue":"8","key":"10.1016\/j.cyto.2023.156433_b0575","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"issue":"21","key":"10.1016\/j.cyto.2023.156433_b0580","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cyto.2023.156433_b0585","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"ObservationalStudy of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623003113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623003113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:10:19Z","timestamp":1736417419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623003113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":118,"alternative-id":["S1043466623003113"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156433","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156433"}}